Home > Haematology > EHA 2019 > Myeloma > Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis

Expert
Prof. Raymond Comenzo, Tufts University, USA
Conference
EHA 2019
Trial
Phase 3, ANDROMEDA

Prof. Raymond Comenzo (Tufts University, USA) presented 1-year follow-up data from the phase 3 ANDROMEDA trial; the combination of subcutaneous daratumumab with cyclophosphamide, bortezomib, and dexamethasone (CyBorD) led to high overall and complete response (CR) rates in patients with newly diagnosed amyloid light chain (AL) amyloidosis.

In the safety run-in single arm phase of ANDROMEDA, 28 patients (median age 68 years; range 35-83 years) with previously untreated AL amyloidosis received daratumumab 1,800 mg (formulated with recombinant human hyaluronidase PH20) administered subcutaneously once a week during cycles 1 and 2, every 2 weeks during cycles 3 through 6, and every 4 weeks thereafter for up to 2 years. Patients also received CyBorD, with cyclophosphamide 300 mg/m2, bortezomib 1.3 mg/m2, and dexamethasone 40 mg, administered once weekly for up to 6 treatment cycles. Researchers followed patients for a median of 341 days (r...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on